IFP Advisors’s Grace Therapeutics GRCE Stock Holding History

IFP Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6	Closed	-$18	–	3463
2024 Q2	$18	Buy	+6	New	+$18	﹤0.01%	3206

Other funds holding GRCE

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

IFP Advisors's GRCE Position: Q3 2024 in Review

IFP Advisors sold out of Grace Therapeutics (GRCE) in Q3 2024, closing a stake of 6 shares — an estimated $18 sold.

IFP Advisors first reported a position in GRCE in Q2 2024 and held it in 1 quarter. The position peaked at $18 in Q2 2024. 12 funds tracked by Wall St. Rank hold GRCE as of Q3 2024.

IFP Advisors reported no remaining Grace Therapeutics position as of Q3 2024 after selling out during the quarter.
IFP Advisors sold 6 Grace Therapeutics shares in Q3 2024, an estimated $18.
IFP Advisors first reported a position in Grace Therapeutics in Q2 2024 and held it in 1 quarter.
IFP Advisors's Grace Therapeutics position peaked at $18 in Q2 2024.
12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2024.

Based on IFP Advisors's 13F filing for Q3 2024, filed 4 Feb 2025.